KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 108 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 4.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,374,124 | +9.1% | 142,692 | +1.9% | 0.16% | -17.9% |
| Q2 2023 | $1,260,000 | +14.5% | 140,000 | 0.0% | 0.20% | -19.6% |
| Q1 2023 | $1,100,400 | +87.8% | 140,000 | +252.4% | 0.25% | +224.7% |
| Q1 2022 | $586,000 | +21.1% | 39,730 | +8.6% | 0.08% | +6.9% |
| Q4 2021 | $484,000 | -71.3% | 36,576 | -62.1% | 0.07% | -39.5% |
| Q3 2021 | $1,685,000 | -27.5% | 96,576 | -0.4% | 0.12% | -36.7% |
| Q2 2021 | $2,323,000 | -69.6% | 96,965 | -67.3% | 0.19% | -26.8% |
| Q1 2021 | $7,629,000 | -66.8% | 296,965 | -75.4% | 0.26% | -74.6% |
| Q4 2020 | $22,965,000 | +47.6% | 1,209,461 | -2.1% | 1.01% | -10.0% |
| Q3 2020 | $15,554,000 | +15.5% | 1,235,471 | +11.0% | 1.13% | +5.0% |
| Q2 2020 | $13,472,000 | +86.0% | 1,113,395 | +17.6% | 1.07% | +96.7% |
| Q1 2020 | $7,242,000 | +91.4% | 946,605 | +345.6% | 0.54% | -11.1% |
| Q4 2019 | $3,783,000 | – | 212,420 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $38,088,000 | 25.57% |
| VHCP Management III, LLC | 637,884 | $14,129,000 | 6.60% |
| Vivo Capital, LLC | 1,359,149 | $30,105,000 | 2.82% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $8,611,000 | 2.78% |
| VHCP Management II, LLC | 376,889 | $8,348,000 | 2.63% |
| Samsara BioCapital, LLC | 118,500 | $2,625,000 | 1.73% |
| ACUTA CAPITAL PARTNERS, LLC | 213,000 | $4,718,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 187,599 | $4,165,000 | 1.54% |
| Ghost Tree Capital, LLC | 300,000 | $6,645,000 | 1.38% |
| Eventide Asset Management | 1,500,000 | $33,225,000 | 1.01% |